Literature DB >> 17768126

Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia.

Massimo Breccia, Giuseppe Cimino, Daniela Diverio, Fabiana Gentilini, Franco Mandelli, Francesco Lo Coco.   

Abstract

We report here a preliminary experience with gemtuzumab ozogamicin (GO) used at low dosage (3 mg/m (2)) in 3 elderly patients with acute promyelocytic leukaemia (APL) who presented molecular relapse and were unfit for intensive chemotherapy.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17768126     DOI： 10.3324/haematol.11329

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  18 in total

Review 1.  Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.

Authors:  Roland B Walter; Frederick R Appelbaum; Elihu H Estey; Irwin D Bernstein
Journal:  Blood       Date:  2012-01-27       Impact factor: 22.113

Review 2.  Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic.

Authors:  Muneera Al-Hussaini; John F DiPersio
Journal:  Expert Rev Hematol       Date:  2014-08       Impact factor: 2.929

3.  Gemtuzumab ozogamicin: time to resurrect?

Authors:  Farhad Ravandi; Elihu H Estey; Frederick R Appelbaum; Francesco Lo-Coco; Charles A Schiffer; Richard A Larson; Alan K Burnett; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2012-09-17       Impact factor: 44.544

4.  Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.

Authors:  Yasmin Abaza; Hagop Kantarjian; Guillermo Garcia-Manero; Elihu Estey; Gautam Borthakur; Elias Jabbour; Stefan Faderl; Susan O'Brien; William Wierda; Sherry Pierce; Mark Brandt; Deborah McCue; Rajyalakshmi Luthra; Keyur Patel; Steven Kornblau; Tapan Kadia; Naval Daver; Courtney DiNardo; Nitin Jain; Srdan Verstovsek; Alessandra Ferrajoli; Michael Andreeff; Marina Konopleva; Zeev Estrov; Maria Foudray; David McCue; Jorge Cortes; Farhad Ravandi
Journal:  Blood       Date:  2016-12-21       Impact factor: 22.113

Review 5.  Future prospects of therapeutic clinical trials in acute myeloid leukemia.

Authors:  Maliha Khan; Armaghan-E-Rehman Mansoor; Tapan M Kadia
Journal:  Future Oncol       Date:  2016-10-24       Impact factor: 3.404

6.  Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.

Authors:  Farhad Ravandi; Eli Estey; Dan Jones; Stefan Faderl; Susan O'Brien; Jackie Fiorentino; Sherry Pierce; Deborah Blamble; Zeev Estrov; William Wierda; Alessandra Ferrajoli; Srdan Verstovsek; Guillermo Garcia-Manero; Jorge Cortes; Hagop Kantarjian
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

Review 7.  Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction.

Authors:  Junmin Li; Hongming Zhu; Jiong Hu; Jianqing Mi; Saijuan Chen; Zhu Chen; Zhenyi Wang
Journal:  Int J Hematol       Date:  2014-06-18       Impact factor: 2.490

8.  Successful repeated treatment of acute myeloid leukemia in early relapse with gemtuzumab ozogamicin alone.

Authors:  Hiroko Tsunemine; Hiroshi Akasaka; Emiko Ishikawa Sakane; Kiminari Ito; Taiichi Kodaka; Takayuki Takahashi
Journal:  Int J Hematol       Date:  2013-12-01       Impact factor: 2.490

Review 9.  Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin.

Authors:  Tetsuya Tanimoto; Masaharu Tsubokura; Jinichi Mori; Monika Pietrek; Shunsuke Ono; Masahiro Kami
Journal:  Invest New Drugs       Date:  2012-09-11       Impact factor: 3.850

Review 10.  Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.

Authors:  Akihiro Takeshita
Journal:  Int J Hematol       Date:  2013-05-26       Impact factor: 2.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.